Determination of piroximone in Plasma and urine by high performance liquid chromatography

Abstract

Abstract A reversed-phase high-performance liquid chromatographic (HPLC) method with UV detection was developed for quantifying piroximone (PI) in plasma and urine. A solid phase extraction of PI simultaneously with an internal standard with an average recovery higher than 86% was needed to avoid endogenous interferences especially in urines from patients with reduced renal functions. The sensitivity limit was 2 ng/ml in plasma and 100 ng/ml in urine. The method was reproducible with intra- and inter-assay coefficients of variations below 7 %. This method was applied to the determination of plasma and urine levels during a pharmacokinetic study in healthy subjects and renally impaired patients. It was found suitable to follow the concentrations until 24 h after a single intravenous infusion of 0.5 mg/kg body weight of piroximone.